atorvastatin has been researched along with everolimus in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Berthier, S; Hartmann, S; Hubert, M; Kovarik, JM; Rordorf, C; Rosenkranz, B; Schneider, W | 1 |
| Avihingsanon, Y; Chancharoenthana, W; Praditpornsilpa, K; Somparn, P; Townamchai, N; Vadcharavivad, S; Wanitchanont, A | 1 |
| Breborowicz, A; Kawka, E; Korybalska, K; Witowski, J | 1 |
1 review(s) available for atorvastatin and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for atorvastatin and everolimus
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Topics: Adult; Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Everolimus; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Mass Spectrometry; Middle Aged; Pravastatin; Pyrroles; Sirolimus | 2002 |
Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Everolimus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Prospective Studies; Pyrroles; Sirolimus | 2014 |
1 other study(ies) available for atorvastatin and everolimus
| Article | Year |
|---|---|
The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions, critical for re-endothelialisation after percutaneous coronary intervention: an in vitro study.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellular Senescence; Cytokines; Everolimus; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |